Ningling Wang, managing partner of the firm’s Shanghai office, has over 20 years ofexperience in various intellectual property fields. Her practice involves patentprosecution, opinions, due diligence, client counseling, licensing, and patentlitigation in the areas of chemicals, chemical engineering, pharmaceuticals, medicaldevices, semiconductor materials, 3D printing, and nanotechnology.
Ningling has extensive experience working with multinational and Chinese companies, providing legal advice on IP portfolio management, due diligence, licensing, litigation, and trade secret protection and enforcement. She has been involved in various cases before the U.S. International Trade Commission (ITC) and U.S. district courts.She also has represented companies with IP enforcement in China, including judicial and customs enforcementactions.
Ningling frequently speaks at conferences and seminars in China and internationally on patent-related topics. She has taught graduate courses on U.S. IP law at Renmin University of China Law School and at Shanghai Jiao Tong University KoGuan Law School, where the curriculum included a mock patent trial. Ningling also served as aprogram professor of law at China Science and Technology University. Currently, she is an adjunct professor with Dalian University of Science and Technology, School of Law.
Experience
Certain Light Emitting Diode Chips, Laser Diode Chips and Products Containing Same
Defended five Chinese LED companies in ITC litigations.
337-TA-674, ITC, Judge Luckern
Certain Sulfentrazone, Sulfentrazone Compositions, and Processes for Making Sulfentrazone
Defended two Chinese agro-chemical companies, defeating a petition for a temporary exclusion order and prevailing at trial, holding the patent invalid and not infringed.
337-TA-914, ITC, Judge Lord
Certain Plant-Derived Recombinant Human Serum Albumins (“rHSA”) and Products Containing Same
Represented respondent Wuhan Healthgen Biotechnology Corporation in patent infringement and Lanham Act litigation involving rice-derived human albumin.
337-TA-1238, ITC, Judge McNamara
Prosecuting patents for startup Hutchison Medipharma
Finnegan prepared and prosecuted patents for startup Hutchison Medipharma in the United States for the treatment of metastatic colorectal cancer.Those patents cover a small molecule, fruquintinib, which received approval in China.
Two-Way Radio Equipment and Systems, Related Software, and Components Thereof
Represented respondents in investigation involving two-way radios and related audio features, including obtaining favorable decision on new designs.
337-TA-1053, ITC, Judge McNamara
Certain Short-Wavelength Light Emitting Diodes, Laser Diodes and Products Containing Same
Defended Chinese LED companies in ITC litigation.
337-TA-640, ITC, Judge Luckern
Professional Activities
·Licensing Executives Society (LES) China
(Special Counsel, 2015-present; Board of Directors, 2009-present)
·American Chamber of Commerce, Shanghai
(Co-Chair, Legal Committee, 2014-2017; Co-Chair, IP Committee, 2010-2012)
·Licensing Executives Society International
(Deputy Treasurer, 2023-present; Board of Directors, 2023-present; Legal Counsel to Board of Directors,2022-2023; Co-Chair, Chemical Energy Environment & Materials (CEEM) Committee, 2018-present; CoChair, Asia Pacific Committee, 2015-2018; Vice-Chair, Asia Pacific Committee, 2010-2015)
·BayHelix Group
(2013-present)
·American Bar Association
·American Intellectual Property Law Association
·Federal Circuit Bar Association
·Order of the Coif
·University of Oregon School of Law
J.D., Order of the Coif, 2001
·Virginia Polytechnic Institute & State University
M.S., Biomedical Engineering,with honors, 1997
·Beijing University of Chemical Technology
B.S., Chemical Engineering,with honors, 1994
Ningling has been recognized by Intellectual Asset Management as a Global Leader, a leader in patent transactions in China, as well as for patent prosecution. She was named a top IP strategist in the IAM Strategy 300 list, which identifies individuals who are leading the way in the development and implementation of strategies that maximize the value of IP portfolios. World Intellectual Property Review named Ningling as a WIPR Leader for patents in China.
